Identity
- Security key
- 14310
- Ticker
- DMAC
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2007-11-29
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- DMAC
Detail
Enriched 2026-08-14 20:47
- Market cap
- $368,851,767.48
- Shares outstanding (class)
- 53,883,345
- Shares outstanding (weighted)
- 53,925,697
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 35
- Location
- MINNEAPOLIS, MN
- Homepage
- https://www.diamedica.com
- Description
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Market cap and share counts drift.